药明康德董事长李革博士荣获CPhI“2019年度CEO”_腾讯新闻
时间:2019-11-11 08:32 来源:百观网

▎药明康德/报道

药明康德董事长革博士荣获CPhI“2019年度CEO”

2019年11月11日——全球知名的世界制药原料展览会(CPhI)日前发布2019年度奖项(CPhI Pharma Awards)评选功效,药明康德董事长兼首席执行官革博士凭借为全球生物医疗研发规模做出的卓越孝敬,荣获“年度CEO”称谓。

药明康德董事长李革博士荣获CPhI“2019年度CEO”_腾讯新闻

CPhI是世界上最大的医药行业盛会之一,本年的CPhI全球大会(CPhI Worldwide)吸引了高出45,000名业内人士参会。CPhI年度奖项旨在表扬那些僵持不懈、开辟创新,为敦促行业成长做出重要孝敬的企业与小我私家。奖项评审委员会独立客观,由全球多位资深专家构成。

评委会暗示,在李革博士的教育下,药明康德已成为全球医药创新规模备受爱崇的赋能者,为医疗康健行业的成长做出了卓越的孝敬。如今,后宫网,药明康德开放式、一体化赋能平台正承载着全球30多个国度,3700多个相助同伴的研发创新项目,不绝加快新药研发历程,为患者带来打破性的治疗方案。

“我很兴奋获此殊荣,也出格感激评委会对药明康德全球化赋能平台的承认,”药明康德董事长兼首席执行官李革博士暗示,“我们很是侥幸可以或许辅佐全球创新相助同伴晋升研发效率,让更多新药、好药早日进入市场,造福全球病患。”

关于药明康德

药明康德(股票代码:603259.SH/2359.HK)为全球生物医药行业提供全方位、一体化的新药研发和出产处事。通过赋能全球制药、生物科技和医疗器械公司,药明康德致力于敦促新药研发历程,为患者带来打破性的诊疗方案。本着以研究为首任,以客户为中心的宗旨,药明康德通过高性价比和高效的研发处事,助力客户晋升研发效率,处事范畴涵盖化学药研发和出产、细胞及基因疗法研发出产、医疗器械测试等规模。今朝,药明康德的赋能平台正承载着来自全球30多个国度的3700多家相助同伴的研发创新项目,致力于将更多新药、好药带给全球病患,早日实现“让天下没有难做的药,难治的病”的愿景。更多信息,请会见公司网站:

Dr. Ge Li Awarded “CEO of the Year” at CPhI Worldwide 2019

November 11, 2019: WuXi AppTec, a leading global provider of R&D and manufacturing services enabling companies in the pharmaceutical, biotechnology and medical device industries, announced today that its Chairman and CEO Dr. Ge Li was awarded “CEO of the Year” at the CPhI Worldwide 2019, a top pharmaceutical event uniting over 45,000 professionals worldwide.

The 2019 CPhI Pharma Awards recognize the innovation and dedication of companies and individuals who are driving the pharmaceutical industry forward. Its Judging Panel is comprised of independent, senior industry experts from around the world, each chosen for their knowledge, objectivity and credibility.

Dr. Ge Li was chosen for his significant contribution to the global biopharma R&D industry. “Under his leadership, WuXi AppTec has become a highly respected contributor to global healthcare innovation. The company is enabling more than 3,700 customers and partners in more than 30 countries by offering open-access capabilities and services, accelerating the discovery and development of new medicines for patients around the world.”

“I’m honored by this award and its recognition of WuXi’s global platform,” said Dr. Ge Li, Chairman and CEO of WuXi AppTec. “It’s been our great privilege to serve our innovative partners around the world and help bring some of the most needed medicines closer to patients.”

About WuXi AppTec

WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec’s open-access platform is enabling more than 3,700 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that "every drug can be made and every disease can be treated." Please visit:

转载本站原创,请注明来源:百观网-百姓观察网

图文来源网络,如有侵权请立即与我们联系,我们会在7天之内及时处理,管理员邮箱:bxgctxs@163.com

新闻排行榜
大家都在看
热门标签
国家互联网信息办 监督管理 运营单位:北京思圆行方文化传媒有限公司
通用网址:www.baiguanw.cn m.baiguanw.cn(手机版)
Copyright © 2011-2020 百姓观察网. 版权所有 未经协议禁止转载具有版权的文章
投稿邮箱:378822888@qq.com
交换友情链接QQ:378822888
京ICP备15038816号-1京公网安备 11010602130036号